Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Pharmaceuticals to Present at 2016 Wedbush PacGrow Healthcare Conference
WATERTOWN, Mass. , Aug. 08, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
WATERTOWN, Mass. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the second quarter ended
View HTML
Toggle Summary Tetraphase Pharmaceuticals Initiates Phase 1 Clinical Trial for TP-6076, a Second-Generation Antibiotic Candidate Highly Active Against MDR Bacteria
WATERTOWN, Mass. , Aug. 01, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the initiation of patient dosing in a phase 1 clinical trial for intravenous (IV) TP-6076, a novel antibiotic candidate being developed for the treatment of serious and
View HTML
Toggle Summary Tetraphase Pharmaceuticals Added to the Russell Microcap® Index
WATERTOWN, Mass. , June 28, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that it was added to the Russell
View HTML
Toggle Summary Tetraphase Pharmaceuticals Presents Antibiotics Pipeline Data at ASM Microbe 2016
Includes Phase 3 Clinical Trial Data from IGNITE1 and IGNITE2
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at 2016 JMP Securities Life Sciences Conference
WATERTOWN, Mass. , June 15, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces Presentation of Data at ASM Microbe 2016
WATERTOWN, Mass. , May 23, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place June 16-20 in Boston , MA.  Presentations will include information
View HTML
Toggle Summary Tetraphase Pharmaceuticals Provides Update on Eravacycline Regulatory and Development Status
- Additional phase 3 clinical trial in cIAI planned to support NDA filing - -Phase 3 clinical trial in cUTI planned for future supplemental NDA - - Company to host conference call at 4:30 p.m. ET today - WATERTOWN, Mass. , May 12, 2016 (GLOBE NEWSWIRE) --   Tetraphase Pharmaceuticals, Inc.
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports First Quarter 2016 Financial Results
WATERTOWN, Mass. , May 04, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the first quarter ended
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present Data at 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
WATERTOWN, Mass. , April 07, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced five data presentations at the 26 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 9-12 in Amsterdam , Netherlands.  Presentations
View HTML